Which EU country pays you fastest —
for your exact product type
Most HealthTech founders pick their entry market based on language or network. Nobody picks based on reimbursement velocity. This interactive tool shows exactly which EU country will pay you first — ranked by product category and regulatory status.
fully mapped
scored
right sequencing
no subscription
Every founder picks their entry market wrong —
and it costs them 2 years.
The most expensive decision a HealthTech founder makes is which EU country to enter first. Almost everyone gets it wrong for the same reason.
Most founders enter the UK because they speak English, or Germany because they met someone at a conference. Neither correlates with reimbursement speed.
A digital therapeutic that gets reimbursed in Germany in 12 months takes 4 years in France. Founders discover this after spending €300k building the wrong relationships.
Entering a slow-reimbursement market first means 2–3 years of burn before your first paid contract. The right sequence cuts that to 6–12 months.
A ranked market map — not generic
strategy advice.
Input your product category and regulatory status. Get a ranked table of EU markets by expected time-to-first-reimbursement, with the specific pathway name and typical timeline.
5 EU markets × 12 product categories — showing expected time to first reimbursement per combination.
- Germany: DiGA, GKV, hospital DRG pathways
- UK: NHS NICE, ICB, SBRI routes
- Netherlands: ZVW, ZonMw, hospital pilots
- Switzerland: KVG/OKP, MiGeL, hospital
- France: HAS, PECAN, forfait numérique
For each product category, the recommended 3-country sequence — which to enter first, second, and third based on reimbursement velocity.
- Fastest-to-revenue entry country per category
- Second market to expand into while first pays
- Common sequencing mistakes to avoid
- Real founder examples per pathway
Fill in your product type, regulatory status, team size, and current evidence — get a personalised market priority score.
- Input your specific situation
- Weighted scoring across 6 factors
- Output: your top 2 entry markets ranked
- Reasoning for each recommendation
| Market | Primary pathway | Expected timeline | Speed rating | Key condition |
|---|---|---|---|---|
| 🇩🇪 Germany | DiGA fast-track | 3–12 months | Fast | BfArM submission quality |
| 🇳🇱 Netherlands | ZVW conditional | 12–18 months | Medium | Health economic evidence |
| 🇬🇧 United Kingdom | ICB local decision | 18–24 months | Medium | NHS trust relationship |
| 🇨🇭 Switzerland | KVG individual case | 24–36 months | Slow | Cantonal variation high |
| 🇫🇷 France | HAS evaluation | 36–48 months | Slow | Full RCT evidence required |
Purchase, receive, make a better
€500k decision today.
Three steps from purchase to knowing exactly which EU market to enter first — and why.
Pay once, receive the full tool via email within 24 hours. PDF matrix, sequencing guide, and scoring worksheet.
- PDF + Excel scoring worksheet
- Delivered to your inbox
- No login, no subscription
Open the worksheet, select your product category and regulatory status, fill in your 6 situation factors.
- Select product category from 12 options
- Input regulatory status
- Answer 6 situational questions
The worksheet outputs your personalised market ranking — which country to enter first, second, and why, based on your specific situation.
- Top 2 markets ranked for your product
- Estimated timeline per pathway
- Key condition to hit in each market
Built for founders making a
market entry decision in the next 90 days.
Every pathway, timeline, and key condition mapped for each market.
The map that changed their
entry strategy.
These are founders who used the map before committing to a market — and changed their sequencing as a result.
This took 6 months to research.
It costs €197.
| Approach | Reimbursement Timing Map | DIY research | Strategy consultant |
|---|---|---|---|
| Time to insight | 15 minutes | 6–12 months | 4–8 week engagement |
| 5 EU markets covered | ✓ All included | Partial — sources fragmented | ✓ Usually yes |
| Product-specific pathways | ✓ 12 categories | Hard to find reliably | ✓ Yes |
| Personalised scoring | ✓ Worksheet included | ✗ Manual calculation | ✓ Part of engagement |
| Investor-ready format | ✓ Use in your deck | ✗ Raw data only | Depends on deliverable |
| Cost | €197 | Hidden cost: 6 months | €5,000–€25,000 |
Questions before purchasing.
You receive a PDF report (the full reimbursement timing matrix and sequencing guide) and an Excel/Google Sheets scoring worksheet. Both are delivered to your email within 24 hour of purchase. No login required, no subscription — one file, yours permanently.
The map is updated quarterly. The current version reflects Q2 2025 pathway timelines, including the updated DiGA fast-track process in Germany, the NHS ICB restructure in the UK, and the French PECAN pilot programme. Reimbursement timelines change slowly — this data will be accurate for 12–18 months.
No. This map focuses specifically on commercial reimbursement timelines — how long it takes to get your first paid patient or contract in each market. It does not replace regulatory advice on CE marking, MDR compliance, or national approval processes. Those are separate and often prerequisites.
Yes — multiple founders have included the market sequencing analysis in their Series A decks. The data is citable and the framework is investor-legible. You can reference it as "GrowthVybz EU Reimbursement Timing Analysis, 2025." No attribution required for internal use.
Digital therapeutics (DTx), AI diagnostics, remote patient monitoring, mental health platforms, hospital workflow tools, medical devices with software, preventive health platforms, clinical decision support, chronic disease management, surgical robotics software, drug discovery AI, and genomics / precision medicine tools.
Yes. If you purchase and find your product category or target markets are not covered in the tool, contact us within 14 days for a full refund. No questions asked. We'd rather refund than have a founder use it for the wrong use case.
Stop guessing which EU market
to enter first.
Every week you spend in the wrong market costs €8–15k in runway. This tool pays for itself before you finish reading it.
Get the map — €197
How much does the wrong
entry market cost you?
Adjust the sliders to your situation. See the real cost of entering the wrong EU market — and what the right sequencing is worth.
Your cost of knowing: €197.